-
Telix 2025 Half-Year Results: Strong commercial performance enables investment for long-term growth
PRNewswire
August 21, 2025
Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces its financial results for the half-year ended 30 June 2025. All figures are in USD unless stated otherwise.
-
Lepu Biopharma (2157.HK) announces 2025 interim results
ACN Newswire
August 21, 2025
Focusing on the field of tumor treatment, innovative biopharmaceutical company Lepu Biopharma Co., Ltd. (Lepu Biopharma or the Company, stock code: 2157.HK) announced its interim results for the first half of 2025.
-
Sisram Medical Reports First-Half 2025 Results: Injectables Surge as AI-Powered EBD Strengthens Segment Positioning
PRNewswire
August 20, 2025
Sisram Medical Ltd announced its unaudited consolidated interim results for the six months ended June 30, 2025 (the "Reporting Period").
-
Cell line development services market to value $2.4 billion by 2030
europeanpharmaceuticalreview
August 11, 2021
New report suggests the cell line development services market will witness a 14.3 percent CAGR between 2021 and 2030.
-
AstraZeneca India’s Q1 net profit declines 45 per cent
expresspharma
August 11, 2021
Revenue from operations stood at Rs 175.40 crores for the quarter under consideration. It was Rs 193.57 crores for the same period a year ago.
-
Moderna records $4.4bn total revenue in Q2 2021
pharmaceutical-technology
August 09, 2021
Moderna has reported total revenue of $4.4bn in the second quarter (Q2) of the fiscal year (FY) 2021, a surge from $67m in the same quarter last year.
-
Lincoln Pharmaceuticals reports 28.33 per cent rise in standalone net profit in Q4 FY21
expresspharma
May 26, 2021
Lincoln Pharmaceuticals has reported net profit of Rs 11.85 crores in Q4FY21 as against the net profit of Rs 9.23 crores in the corresponding period last year, growth of 28.33 per cent.
-
China Pharma Holdings, Inc. Reports 33% YoY Increase in First Quarter 2021 Revenue
prnasia
May 17, 2021
China Pharma Holdings, Inc., a specialty pharmaceutical company, announced financial results for the quarter ended March 31, 2021.
-
Takeda Pharmaceutical reports decline in FY2020 revenue
pharmaceutical-technology
May 13, 2021
Takeda Pharmaceutical has reported a 2.8% year-on-year (YOY) decrease in its reported revenue to JPY3,197.8bn ($29.4bn) during the fiscal year 2020 (FY2020) ended 31 March 2021.
-
Seegene reports solid results in the first quarter of 2021 with KRW 351.8 billion
prnasia
May 12, 2021
Seegene Inc., a molecular diagnostics company reported its financial results for the first quarter of 2021, with reports showing robust earnings.